Omada Health saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 77 to 81.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's proprietary RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matches up against the rest of the market.
History reveals that the top-performing stocks typically have an 80 or higher RS Rating as they begin their biggest runs.
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to establish and enter a buying range in heavy volume.
Omada Health showed 0% earnings growth in its most recent report. Sales increased 49%.
Omada Health holds the No. 12 rank among its peers in the Medical-Services industry group. GeneDx Holdings, Hims & Hers Health and InfuSystem Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
